A method for continually sensing at least one analyte. The method includes bringing a sample including at least one analyte into contact with at least one sensor having an electrode and a plurality of aptamers that are capable of binding to the analyte. At least some of the aptamers each carry at least one tag (such as a redox tag), wherein each tag changes in at least one parameter when analyte binds to its associated aptamer (such as by being brought closer to or further from, on average, the electrode (which results in a measurable change in electrical current that can be translated to a measure of presence or concentration of the analyte). The method also includes applying a first electronic waveform to the at least one sensor, wherein the first electronic waveform is associated with a first binding affinity between the analyte and the plurality of aptamers. The method also includes applying a second electronic waveform to the at least one sensor, wherein the second electronic waveform is associated with a second binding affinity between the analyte and the plurality of aptamers. The first electronic waveform and second electronic waveform are different waveforms, and the first binding affinity and second binding affinity differ by at least 2X.
The present invention is directed to a method and apparatus for simultaneously implementing mechanochemical and electrochemical synthesis conditions. With respect to the method, the method may be configured to improve one or more reaction metric such as increasing product yield, reducing organic solvent consumption, reducing the reaction time, reducing the amount of, or completely eliminating, at least one toxic reagent or solvent, or enabling electrochemical synthesis of the chemical product without complete solubility of the organic substrate in the organic solvent. With respect to the apparatus, the apparatus is configured to define a reaction area between an anode and cathode that can be mechanochemically agitated to improve synthesis without disrupting the electrochemical reaction.
Provided herein are compositions including ionizable lipids and lipid nanoparticles comprising the ionizable lipids. The ionizable lipids may have a general structure according to formula I: (I). Lipid nanoparticles generally include the ionizable lipid according to formula (I); a helper lipid; a sterol; and a PEGylated lipid conjugate. The ionizable lipids and lipid nanoparticles may be used to carrier cargo for a vaccine.
C07D 211/62 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
4.
Single Waveform, Continuous Squarewave Voltammetry for Optimal Calibration Free Sensing
A method of measuring sensor response for a sample is disclosed. The sample is exposed to an electrochemical aptamer-based (EAB) sensor, where the sensor includes an electrode and one or more aptamers having redox tags. Next, an interrogation is performed by applying an abrupt voltage pulse to the electrode. Two or more data samples are collected at different time values, where each data sample is a redox tag current value. Then at least one measure of the sample is identified using the data samples.
A complex of curcumin with a polyphenolic macrocyclic host is disclosed. The macrocyclic host is a resorcin[4] arene. In one approach, the polyphenolic macrocyclic host is calix[8] arene. In another approach, the polyphenolic macrocyclic host is tert-butylcalix[8] arene.
Methods of treating lung cancer in a subject in need thereof are provided, including administering to the subject an effective amount of an imidazolate gold compound according to Formula I, or a pharmaceutically acceptable salt, racemate, or enantiomer thereof:
Methods of treating lung cancer in a subject in need thereof are provided, including administering to the subject an effective amount of an imidazolate gold compound according to Formula I, or a pharmaceutically acceptable salt, racemate, or enantiomer thereof:
Methods of treating lung cancer in a subject in need thereof are provided, including administering to the subject an effective amount of an imidazolate gold compound according to Formula I, or a pharmaceutically acceptable salt, racemate, or enantiomer thereof:
wherein R1 and R2 are independently selected from the group consisting of halo, cyano, hydroxyl, carboxyl, alkyl, aryl, esteryl, amidyl, and alkoxyl. Methods of inducing ferroptosis in a lung cancer cell and pharmaceutical compositions are also provided.
A method of determining platelet aggregation forces is provided. The method involves embedding tension sensor-coated microbeads in platelet clots and observing fluorescent signals from the microbeads that correspond to contractile forces exerted on the tension sensor-coated microbeads to report platelet aggregation forces. In one embodiment, the platelet aggregation forces are used as biomechanical markers to evaluate platelet functions. In another embodiment, the fluorescent signals can be read directly by a plate reader.
G01N 11/14 - Investigating flow properties of materials, e.g. viscosity or plasticityAnalysing materials by determining flow properties by moving a body within the material by using rotary bodies, e.g. vane
G01N 33/86 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving blood coagulating time
B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
G01N 33/49 - Physical analysis of biological material of liquid biological material blood
9.
Lift-Based Peel Separation for Inverted Vat Photopolymerization 3D Printing
A method of inverted SLA 3D printing with a printing device is disclosed. The method involves a) lifting a thin elastic membrane to an elevated position within a resin filled vat via vertical movement of an optical module, the resin filled vat, or both. b) allowing resin on the thin elastic membrane to cure as a current layer, the layer being attached to a printed part, and c) peeling the thin elastic membrane from the current layer by lowering the optical module, raising the resin filled vat, or both.
B29C 64/124 - Processes of additive manufacturing using only liquids or viscous materials, e.g. depositing a continuous bead of viscous material using layers of liquid which are selectively solidified
A device and method for detecting the presence of, or measuring the concentration or amount of, at least one large analyte in a sample fluid. The device has at least one electrode, a sample fluid and a plurality of aptamers capable of binding to the analyte. The aptamers are physically bound to the device. In addition, the aptamers each include at least one redox tag and also, the aptamers have two or more binding portions that bind to two or more distinct binding sites on the analyte in the sample fluid.
Certain aspects of the disclosure provide systems and methods for generating predictions of mood disorder. For example, one method may include presenting a set of stimuli and receiving a set of ratings for the set of stimuli from a subject. The method further includes determining a set of judgment variables based on the set of ratings. The method further incudes generating a mood disorder prediction based on the set of judgment variables and treating the subject based on the mood disorder prediction.
G16H 50/00 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
G16H 10/00 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data
G16H 40/00 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices
G16H 20/70 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mental therapies, e.g. psychological therapy or autogenous training
H01M 12/06 - Hybrid cellsManufacture thereof composed of a half-cell of the fuel-cell type and of a half-cell of the primary-cell type with one metallic and one gaseous electrode
A method to prevent calcification of an injury site in a subject is provided. The method involves injecting the injury site with a composition including a hydrogel and the hydrogel comprises poly(aspartic acid) (PASA). In one embodiment, the hydrogel is formed by combining thiol- functionalized PASA with one or more maleimide-functionalized crosslinkers. Additionally, a method to prevent premature bone fusion in a pediatric subject's skull is provided. The method involves injecting one or more cranial sutures of the skull with a composition including a hydrogel and the hydrogel comprises poly(aspartic acid) (PASA).
C08J 3/09 - Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques in organic liquids
C08J 3/24 - Crosslinking, e.g. vulcanising, of macromolecules
C08L 29/02 - Homopolymers or copolymers of unsaturated alcohols
14.
Electrochemical Aptamer Sensors with Signal Amplification Via Multiple Redox Tags
A device for detecting the presence of, or measuring the concentration or amount of, at least one analyte in a sample fluid is disclosed. The device includes at least one electrode; a sample fluid; and a plurality of affinity-based probes capable of binding to the analyte, wherein the affinity-based probes each carry a plurality of redox tags. Further, the detection or measurement of an analyte is caused by analyte binding to the affinity-based probe which further causes a change in electron transfer from the redox tags.
A device for modeling a brain tumor microenvironment and testing therapeutic efficacy is provided. The device includes a vascular tissue model and an ultrasound device that is capable of delivering focused ultrasound insonation. The vascular tissue model includes a rigid 3D printed scaffold. The scaffold includes one or more scaffold microfluidic channels, two or more inlets, and a central chamber. The central chamber contains a hydrogel or other biocompatible scaffolds. The hydrogel includes one or more hydrogel microfluidic channels as well as living cells.
Certain aspects of the disclosure provide systems and methods for diagnosing and treating chronic liver disease and portal vein thrombosis. In particular, methods may include measuring levels of one or more proteins, including factor V, factor VIII, protein C, protein S, D-dimer, sP-selectin, or asTF in a biological sample from a subject and determining a CLD score based on the levels of the one or more proteins, whereby, a CLD stage may be determined based on the CLD score. In some aspects, methods may include determining a PVT score based on levels of the one or more proteins in the biological sample. In some aspects, methods further include treating CLD and/or PVT.
A novel endonasal method for occipitocervical fusion is provided. This new method provides a minimally invasive advance in the ability of surgeons to treat pathology of the craniocervical junction. The method uses an implant system comprising a body having a spacer section that engages with the occipital condyle and a plate section that engages with the C1 lateral mass. Fasteners fix the plate section with the occipital condyle the plate section with the C1 lateral mass.
A device for detecting or measuring at least one large analyte in a sample fluid. The device includes at least one electrode; a sample fluid; and a plurality of aptamers capable of binding to the analyte, wherein the aptamers are physically bound to the device. A majority of the aptamers comprise a first molecule and a second molecule. The first molecule is a redox tag or redox molecule. The second molecule, when it is brought into proximity of the first molecule, results in decreased redox electron transfer with an electrode at a given voltage.
A novel method for treating hyponatremia or polycystic kidney disease in a mammal is disclosed. The method involves administering to the mammal in need of such treatment a therapeutically effective amount of an adenine analog selected from the group consisting of: 2-chloro-6-aminopurine, its tautomer, racemate, optical isomer and/or pharmaceutically or nutritionally acceptable salt thereof, and a pharmaceutical carrier, 6-(dimethylamino) purine, its tautomer, racemate, optical isomer and/or pharmaceutically or nutritionally acceptable salt thereof, and a pharmaceutical carrier; and combinations thereof.
Provided herein is a device for rapid fixation and embedding of a biological specimen, the device including a barrel having a first end and a second end, the first end receiving a plunger and the second end opening to a compartment defining a block mold; and a plunger for inserting in the barrel, the plunger having a first end, a second end, and an interior conduit connecting the first and second ends, wherein the first end of the plunger connects to a vacuum source and the second end of the plunger includes a filter barrier between the interior conduit of the plunger and a receptacle for receiving, fixing, and embedding the specimen, the receptacle defined inside the barrel when the plunger is disposed in the barrel. Also provided are a system and method for rapid fixation and embedding of a biological specimen.
A continuous sensing device configured for sensing both oxygen and at least one other analyte in a fluid in a single measurement scan comprising a first electrode. A method of measuring both oxygen concentration and the concentration of at least one other analyte using sensing device comprising a first electrode. The method comprises measuring current in a first potential zone, wherein that current correlates to concentration of the at least one other analyte, and measuring current in a second potential zone, wherein that current correlates to a concentration of oxygen. The method may further comprise configuring the first electrode to measure a greatest measured current over baseline to a maximum within one or both of the two potential zones for a duration.
Systems, methods, and computer program products for minting non-fungible tokens (52). The system includes a computing device (18, 24) that receives a dynamic uniform resource identifier (URI) (64) including a unique identifier and a hostname that identifies a host system (12). In response to receiving the dynamic URI (64), the computing device (18, 24) transmits data to the host system (12) identified by the hostname. The data includes the unique identifier and at least one of a time the computing device (18, 24) received the URI (64) and a physical location of the computing device (18, 24) when the URI (64) was received. In response to receiving the data from the computing device (18, 24), the host system (12) mints a non-fungible token (52) on a blockchain (30) that documents at least one of the time the computing device (18, 24) received the URI (64) and the physical location of the computing device (18, 24) when the URI (64) was received.
G06F 21/73 - Protecting specific internal or peripheral components, in which the protection of a component leads to protection of the entire computer to assure secure computing or processing of information by creating or determining hardware identification, e.g. serial numbers
G06F 21/33 - User authentication using certificates
In one aspect of the present invention, a genetically modified Anti-Mullerian Hormone (AMH) is disclosed where one or more cysteine residues in the prodomain are replaced with amino acid residues other than cysteine. In one embodiment, one or more cysteine residues in the prodomain are replaced with serine residues. In one embodiment, cysteine 241 of the prodomain is replaced with a serine residue.
METHODS FOR SELF-SEEDED HYDROTHERMAL GROWTH OF MFI ZEOLITE NANOSHEETS AND NANOSHEET ASSEMBLIES AND FOR TILING NANOSHEET ZEOLITE PLATES ON POLYMER SUPPORTS
The present invention relates to methods for synthesizing MFI zeolite nanosheet (ZN) assemblies and open-pore ZN plates and for tiling ZN plates on polymer supports. Methods for producing ZN assemblies and ZN plates may reduce or eliminate the need to synthesize nanoparticle (NP) seed-evolved single-crystal zeolite nanosheets (ZNs) as an intermediate product. Methods for tiling ZN plates on polymer supports may produce ZN plate-tiled (ZNPT) membranes with reduced permeation through intercrystalline spaces.
B01J 20/10 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising inorganic material comprising silica or silicate
B01J 20/28 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof characterised by their form or physical properties
B01J 20/30 - Processes for preparing, regenerating or reactivating
C30B 7/14 - Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions the crystallising materials being formed by chemical reactions in the solution
A method of making a polyurethane polymerized high internal phase emulsion (polyHIPE) is disclosed. The method involves preparing a polyurethane prepolymer and crosslinking the polyurethane prepolymer using a thiol-alkene Michael addition, producing a polyurethane polymerized high internal phase emulsion. In one embodiment, the polyurethane prepolymer is prepared by reacting diisocyanate and trimethylolpropaneallylether (TMPAE).
C08G 18/67 - Unsaturated compounds having active hydrogen
C08G 18/73 - Polyisocyanates or polyisothiocyanates acyclic
C08G 18/75 - Polyisocyanates or polyisothiocyanates cyclic cycloaliphatic
C08G 18/76 - Polyisocyanates or polyisothiocyanates cyclic aromatic
C08G 18/87 - Chemically modified polymers by sulfur
C08J 9/28 - Working-up of macromolecular substances to porous or cellular articles or materialsAfter-treatment thereof by elimination of a liquid phase from a macromolecular composition or article, e.g. drying of coagulum
26.
SYSTEMS AND METHODS FOR AERIAL VEHICLES EQUIPPED WITH CONTROL MOMENT GYROSCOPES
An aerial vehicle system includes one or more actuators; a processor; and a non-transitory, computer-readable storage medium communicatively coupled to the processor. The processor is configured to: receive one or more predetermined state values, wherein the one or more predetermined state values include one or more user values associated with aerial instability including turbulence, motion sickness, or any combination thereof; receive one or more sensing parameters; compare the one or more predetermined state values with the one or more sensing parameters; generate, based on the comparison, one or more signals to stabilize an aerial vehicle; transmit the one or more signals to the one or more actuators; and control, in response to the one or more signals, stabilization of the aerial vehicle by the one or more actuators.
B64C 13/16 - Initiating means actuated automatically, e.g. responsive to gust detectors
B64C 27/82 - RotorcraftRotors peculiar thereto characterised by the provision of an auxiliary rotor or fluid-jet device for counter-balancing lifting-rotor torque or changing direction of rotorcraft
G01S 17/50 - Systems of measurement based on relative movement of target
A method of making sensors with a plurality of aptamers and performing continuous measurements with the sensors is provided. The method involves fabricating a plurality of sensors where each sensor has at least one electrode with a plurality of aptamers attached to the electrode surface. A portion of the plurality of sensors is calibrated and a portion of the plurality of aptamer sensors is identified as being commercial quality ("the product portion"). At least one set of calibration data gathered from the calibration of the plurality of sensors is associated mathematically to the product portion.
A61B 5/1495 - Calibrating or testing in vivo probes
A61B 5/1486 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using chemical or electrochemical methods, e.g. by polarographic means using enzyme electrodes, e.g. with immobilised oxidase
Supramolecular inclusion complexes comprising sulfonato methylresorcinarenes according to Formula I and a fluoroquinolone compound are provided. Also provided are pharmaceutical compositions comprising the supramolecular complexes and methods of using the supramolecular complexes to treat bacterial infections, kill or inhibit growth of bacteria, and disrupt bacterial biofilms.
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
29.
INDUSTRIAL HEAT PUMPS FOR TRANSPORTING HEAT WITH A REFRIGERANT AND A METHOD OF OPERATING THE SAME
An industrial heat pump includes an evaporator configured to transfer heat into a refrigerant, a condenser configured to transfer the heat out of the refrigerant to a heat sink, a first fluid path, a second fluid path, and an expansion valve defining a portion of the first fluid path. The industrial heat pump includes a thermal storage unit defining a portion of the second fluid path. The thermal storage unit is configured to receive and store heat from the refrigerant in the second fluid path. The industrial heat pump includes a compressor defining a portion of the second fluid path between the thermal storage unit and the condenser. The heat received by the thermal storage unit causes a portion of the refrigerant to phase change from a gas to a liquid allowing for wet compression of the refrigerant through the compressor where the refrigerant phase changes to a gas.
Described are sensing devices and methods that continuously sense an analyte included in an interstitial fluid. The device includes at least one ex-vivo sensor specific to the a least one analyte in interstitial fluid. The device further includes at least one sample collection component in the dermis that defines at least in part an advective pathway to transport interstitial fluid to the at least one sensor. The advective pathway is air-tight, and at least one integrated pump applies negative pressure to cause advective transport of interstitial fluid from the dermis, to the sensor, and onto the pump.
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
A61B 5/1455 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using optical sensors, e.g. spectral photometrical oximeters
A61B 5/1477 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using chemical or electrochemical methods, e.g. by polarographic means non-invasive
A three-dimensional microfluidic device is provided. The device includes an array of fluid transporting channels formed in a permeable gel. The channels allow both direct circulation flow and diffusion flow from a channel into the gel. The diffusion flow is lateral to the direction of the channel. The device also includes one or more fluid movement devices capable of controlling the circulation flow to enable control of flow pattern in the permeable gel. The device further includes one or more types of organoids cultured in the device.
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (USA)
UNIVERSITY OF CINCINNATI (USA)
Inventor
Deng, Zicheng
Kalinichenko, Vladimir
Shi, Donglu
Abstract
Polymers based on a poly(β-amino) ester (PBAE) backbone are provided, with improved targeting of the lung endothelium following parenteral delivery. The disclosed polymers are polymers of a primary amine (A2), a secondary amine (A1), a diacrylate (D) and at least one end-capping hydrophilic compound (C) such as amine. The polymer is halogenated (hereinafter, halogenated PBAE polymer), preferably, fluorinated. The hydrophobic PBAE backbone is end capped with a hydrophilic compound by covalent attachment of these capping agents to the PBAE backbones via Michael Addition to form a halogenated PBAE. The disclosed polymers can be used to encapsulate/incorporate an active agent for targeted delivery to lung endothelial cells.
A nozzle (30) for a jet engine (32) is disclosed. The nozzle (30) includes at least one sweeping jet actuator (10) operatively coupled to the nozzle (30). The sweeping jet actuator (10) has an inlet opening (14) and a discharge slot (26). The inlet opening (14) is configured to receive a supply of air (40) and the discharge slot (26) is configured to discharge that supply of air in a sweeping motion (42) into and interacting with an air flow (36) moving through the nozzle (30). A jet engine (32) with a nozzle (30) and a sweeping jet actuator (10) coupled to the nozzle (30) is also disclosed. A method of operating a jet engine (32) having a nozzle (30) with a sweeping jet actuator (10) is further disclosed.
F02K 1/34 - Plants characterised by the form or arrangement of the jet pipe or nozzleJet pipes or nozzles peculiar thereto using fluid jets to influence the jet flow for attenuating noise
Methods, systems, and computer program products for providing an educational environment using agentic artificial intelligence. A prompt is received from a system user (220), and a response to the prompt is generated using a large language model (208). The response includes raw content defining a clinical scenario consistent with the prompt. The raw content is interpreted using fuzzy logic (213) to generate filtered content based on the first raw content, and the filtered content is displayed to the user (220). In response to the user (220) inputting additional prompts responsive to the filtered content, the large language model (208) generates another response including raw content that defines an updated clinical scenario consistent with both the initial clinical scenario and the additional prompts received from the user. The fuzzy logic (213) generates new filtered content based on the new raw content, and this filtered content is displayed to the system user (220).
The present invention relates to a catalyst for degrading perfluorooctanoic acid (PFOA) in solution, comprising bimetallic catalytic nanoparticles immobilized on a substrate. The nanoparticles may include metals such as iron, manganese, cobalt, nickel, copper, and titanium. The substrate may be an ion exchange resin, such as an anion exchange resin. Methods for synthesizing the catalyst may include dissolving metal salts in water, titrating with a reducing agent, and immobilizing the nanoparticles on the resin. Methods of degrading PFOA include providing a plurality of bimetallic catalytic nanoparticles to a first solution comprising perfluorooctanoic acid. The method may optionally include additional steps for immobilizing the bimetallic catalytic nanoparticles, synthesizing the bimetallic catalytic nanoparticles, purging the first solution with an inert gas, and/or adjusting the pH of the first solution.
A stent for a bladder is provided. The bladder includes a drainage tube, a shell with flexible leaf-shaped sections ("spring leaves") and a string tether. The shell surrounds the drainage tube and the tether is attached to the drainage tube. In addition, the spring leaves are attached at the top of the drainage tube and the spring leaves are attached at the bottom of the shell by a ring with an opening through which the drainage tube can pass freely.
Myopeptides are provided, which include a myosin S2 fragment having at least 90% sequence identity to an amino acid sequence consisting of VKEMTERLEDEEEMNAELTAKK (SEQ ID NO: 1); and, optionally, a cardiac-homing peptide tag. Also provided are pharmaceutical compositions and methods of use of the myopeptides and pharmaceutical compositions in the treatment of heart failure.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
A61K 9/00 - Medicinal preparations characterised by special physical form
A method of incorporating one or more linkers into a biomaterial with one or more ketone units is disclosed. The method involves reacting a linker-containing material selected from the group consisting of thiol-containing compositions, thioketal-containing compositions, selenol-terminated compositions and combinations thereof with the biomaterial in the presence of an acid catalyst.
The present invention relates to a device for continuous sensing of at least one analyte in a test fluid that is resistant at least one of desorption of a first plurality of molecules, including a plurality of aptamers and a blocking layer, and fouling during use of the device when exposed to temperatures greater than or equal to 30° C. for at least 3 days. Another aspect of the invention is a method of providing fouling resistance to an aptamer sensor device wherein the blocking layer and aptamer are resistant to at least one of desorption from the electrode and fouling during use of the aptamer sensor when exposed to temperatures greater than or equal to 30° C. for at least 3 days.
The present disclosure concerns fluorescent probes of pyridine, quinolinium and piperazine covalently linked as a small molecule probe. The probes can be administered to cells and are readily uptaken thereby. The probes locate particularly into endolysosomes. The probes provide two types of fluorescence with pH-sensitive photophysical properties, which in turn allows for the observation and analysis of changes occurring during varying stages of interest. The dual fluorescence provides for simultaneous monitoring of two fluorescence signals in endolysosomes at different stages of interest and minimizes the interference from various microenvironments.
C07D 215/02 - Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
C07D 241/04 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
C07D 213/02 - Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
C07D 215/12 - Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
G01N 31/22 - Investigating or analysing non-biological materials by the use of the chemical methods specified in the subgroupsApparatus specially adapted for such methods using chemical indicators
41.
Shelf-Stable Sterilization of Aptamer-Sensors for In-Vivo Measurement in Humans
A method of measuring analytes in a subject in vivo for a period of time is provided. The method involves storing a device. The device includes at least one sensor comprising an aptamer material; at least one feature for coupling said sensor to an analyte in the subject in vivo; at least one sterilization state that imparts sterilization on at least one component of the device; at least one sterile packaging material enabling a storage state; and at least one aptamer storage material. The sensor is contained in the sterile packaging material and the storage material is anhydrous. Further, wherein the sensor and the feature are sterile. The method further involves removing the sterile packaging material from the device and using the feature to couple the sensor to an analyte in the subject.
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
A61B 5/1473 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using chemical or electrochemical methods, e.g. by polarographic means invasive, e.g. introduced into the body by a catheter
42.
ELECTROCHEMICAL APTAMER SENSOR MONOLAYER INCUBATION WITH IMPROVED STABILITY
A method of fabricating an electrochemical aptamer sensor is provided. The method includes incubating an electrode including a sensing monolayer. The sensing monolayer includes at least a plurality of aptamers and at least one weakly bonded constituent. The method further includes removing the at least one weakly bonded constituent from the sensing monolayer by applying at least one perturbation mechanism to the sensing monolayer while incubating the electrode.
An electrocatalyst ink composition is provided. The ink composition includes a liquid vehicle, particles with at least one electrocatalyst metal, and at least one compound having a phenolic moiety. In various embodiments, the compound comprising a phenolic moiety is resorcinol and the electrocatalyst metal is a platinum-bismuth alloy.
A device for detecting or measuring at least one large analyte in a sample fluid is provided. The device includes at least one substrate and a plurality of multi-bond aptamers capable of binding to the analyte. The aptamers are physically bound to the substrate and include at least one tag capable of providing a signal. Also, the multi-bond aptamer has a change in geometry when the multi-bond aptamer binds to the analyte. Further, the tag has a resulting change in signal resulting from the analyte binding to the multi-bond aptamer and associated change in geometry.
An apparatus may comprise a controller programmed to establish a connection with an integrated circuit, program a plurality of cross-coupled look up tables of the integrated circuit to generate a plurality of memory cells, each pair of cross-coupled look up tables comprising one memory cell, and associate a plurality of the memory cells with a digital fingerprint of the integrated circuit, a value of each memory cell after startup of the integrated circuit comprising one bit of the digital fingerprint.
G06F 21/73 - Protecting specific internal or peripheral components, in which the protection of a component leads to protection of the entire computer to assure secure computing or processing of information by creating or determining hardware identification, e.g. serial numbers
G06F 30/34 - Circuit design for reconfigurable circuits, e.g. field programmable gate arrays [FPGA] or programmable logic devices [PLD]
H04L 9/32 - Arrangements for secret or secure communicationsNetwork security protocols including means for verifying the identity or authority of a user of the system
22 separation is provided. The sorbent chemical includes an amine functionalized with an epoxide chemical impregnated onto a mesoporous silica support. The amine is selected from the group consisting of polyethylenimine, tetraethylenepentamine, and pentaethylenehexamine. Also, the epoxide chemical is selected from the group consisting of isobutylene oxide (TBO), dimethyl- 1,2-epoxybutane (DMEB), epoxy octane (EO), styrene oxide (SO), phenyl glycidyl ether (PGE), glycidyl 4-methoxyphenyl ether (GMPE), butyl glycidyl ether (BGE), glycidyl isopropyl ether (GIPE), 2- (tert-butoxymethyl oxirane) (TBGE), and neopentyl glycol diglycidyl (NGD).
B01J 20/10 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising inorganic material comprising silica or silicate
C08G 59/18 - Macromolecules obtained by polymerising compounds containing more than one epoxy group per molecule using curing agents or catalysts which react with the epoxy groups
A method of treating pancreatic adenocarcinoma in an individual is disclosed. The method involves administering to the individual a therapeutically effective amount of a therapeutic agent comprising recombinant acid sphingomyelinase. In one embodiment, the therapeutic agent further includes one or more compositions selected from the group consisting of modified enzymes, fusion proteins and constitutively active mutants. In another embodiment, the therapeutic agent further includes a pharmaceutically acceptable excipient.
A61P 35/04 - Antineoplastic agents specific for metastasis
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
Disclosed herein are compositions and methods for treating an individual having a leukemia. In certain aspects, the methods may include administering an I0DVA1 compound and ponatinib to an individual in need thereof for treatment of a leukemia, which may include, for example, TKI-resistant leukemia, TKI-resistant Ph+ B-ALL, Chronic Myelogenous Leukemia (CML), Ph-Positive Acute Lymphoblastic Leukemia (ALL), Ph-like ALL, Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML), MLL-rearranged B-ALL, and VAV3 positive leukemia.
A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
A61K 31/341 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/5025 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
A61P 35/02 - Antineoplastic agents specific for leukemia
49.
SYSTEMS AND METHODS FOR PREDICTING AIRPORT PASSENGER FLOW
A computing device includes a controller to receive passenger data based on airport scans of boarding passes, determine time until takeoff data for passengers, determine passenger flow histograms based on the time until takeoff data, transform the passenger flow histograms into continuous passenger flow profile curves, determine input similarity matrices between a first flight and past flights having scheduled departures on the same day of the week based on input similarity scores, determine output similarity matrices between the first flight and the past flights based on passenger flow profile curves associated with the first flight and the past flights, determine past flights that are most similar to the first flight based on the input similarity matrices and the output similarity matrices, and determine a predicted passenger flow profile curve for the first flight based on the passenger flow profile curves associated with the most similar past flights.
G06Q 10/04 - Forecasting or optimisation specially adapted for administrative or management purposes, e.g. linear programming or "cutting stock problem"
G06Q 10/02 - Reservations, e.g. for tickets, services or events
G06Q 50/40 - Business processes related to the transportation industry
A biphasic membrane-free battery and a triphasic membrane-free battery are provided. The biphasic membrane-free battery includes a housing structure housing: a catholyte phase having a cathode, and an anolyte phase having an anode, the catholyte phase contacting the anolyte phase along an interface. The triphasic membrane-free battery includes a housing structure housing: a catholyte phase having a cathode, and an anolyte phase having an anode, and an electrolyte phase between the catholyte phase and the anolyte phase.
A novel method of making a 3D-shaped 3D graphene (3D2G) is disclosed. The method involves a) 3D printing a catalyst slurry via Direct Ink Writing (DIW); b) depositing the printed slurry using chemical vapor deposition (CVD) to produce a nickel-graphene composite; and c) etching the nickel-graphene composite. The resulting composite is a porous, binder-free structure of pure 3D2G. In one embodiment, the catalyst slurry comprises nickel particles mixed with an organic solvent, a polymer, and a plasticizer. In another embodiment, the organic solvent is dichloromethane, the polymer is poly lactic-co-glycolic acid and the plasticizer is dibutyl phthalate.
A device for continually sensing at least one analyte in a sample fluid via measurement of the analyte is provided. The device includes at least one sensor with surface having a plurality of aptamers that bind to the analyte. The aptamers carry at least one tag that changes in at least one electrical parameter as analyte binds to the aptamers. The surface also has a protective layer that protects the surface from fouling in between the aptamers. The protective layer includes a monolayer of molecules that form a boundary with the sample fluid and the monolayer is a mixed conductivity monolayer.
G01N 33/542 - ImmunoassayBiospecific binding assayMaterials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
53.
IONIZABLE LIPIDS, LIPID NANOPARTICLES FOR MRNA DELIVERY AND METHODS OF MAKING THE SAME
A composition including ionizable lipids is provided. Also provided is a composition forming lipid nanoparticle, wherein the composition includes the ionizable lipid, a helper lipid, a sterol, and a PEGylated lipid conjugate. Also provided are methods of making the ionizable lipids. The ionizable lipids can include 2AEOAP2, 2AEOAP4, 2AELAP2, 2AELAP4, Lipid 16A, Lipid 16B, Lipid 16C, Lipid 16B, and Lipid 20B.
C07D 211/62 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
54.
ELECTROCHEMICAL APTAMER SENSORS WITH APTAMERS BOUND ADJACENT TO THE ELECTRODE
An aptamer sensing device is provided. The aptamer sensing device 200 includes at least one electrode 220. The aptamer sensing device further includes at least one binding feature 230. The aptamer sensing device further includes a plurality of aptamers 270 attached to the binding feature and not individually attached to the electrode, the aptamers further having an attached redox couple 272. The aptamer sensing device is configured to accept a sample fluid 242 including at least one analyte, and the binding feature is positioned relative to the electrode such that a binding of the analyte to the aptamers causes a shape change configuration in the binding feature that increases or decreases a charge transfer from the redox couple to the electrode.
A device for continually sensing at least one analyte in a sample fluid via measurement of the analyte is provided. The device includes an optically transparent component adapted for in-vivo placement. The device also includes a plurality of aptamers bound to the optically transparent component. The aptamers are capable of binding to the analyte. Also, the aptamers carry at least one tag that changes in at least one optically measurable property when the aptamers bind to the analyte. Additionally, an optical source and detector coupled to the optically transparent component can measure the optically measurable property of the aptamers.
A device for continually sensing at least one analyte in a sample fluid via measurement of the analyte is provided. The device has a sensor with a surface having a plurality of aptamers that bind to the analyte. The plurality of aptamers carries at least one tag. The surface also has a protective layer that protects the surface from fouling in between the aptamers. The protective layer has a monolayer of molecules that form a boundary with the sample fluid. Further, the monolayer of molecules is a mixed charge monolayer.
G01N 33/542 - ImmunoassayBiospecific binding assayMaterials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
Certain aspects described herein include systems and methods for predicting vaccine uptake. A method includes presenting, to a user via a user interface, a set of stimuli; and receiving, from the user via the user interface, a set of ratings associated with the set of stimuli, wherein each respective rating in the set of ratings corresponds with a respective stimuli in the set of stimuli. The method further includes determining a set of judgment variables based on the set of ratings; and generating, with a machine learning model, a vaccine uptake prediction based on the set of judgment variables, wherein the machine learning model is trained to determine a vaccination status of users.
G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
G16H 50/80 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for detecting, monitoring or modelling epidemics or pandemics, e.g. flu
58.
BIOSENSOR FOR PLACEMENT AT SKIN DEPTHS THAT ARE NOT PREDETERMINED
A wearable device for continuous monitoring of at least one analyte is provided. The device includes a plurality of aptamer sensors for a specific analyte and a means to determine at least one location measurement. The sensors are capable of being placed in a distinct location with respect to depth into a user's skin. The location measurement has a distinct measurement response between at least two skin tissues such as epidermis, dermis, and hypodermis. Also, at least one of the sensors is capable of being placed at a distinct tissue location.
A61B 5/1473 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using chemical or electrochemical methods, e.g. by polarographic means invasive, e.g. introduced into the body by a catheter
Provided herein are methods of potentiating an effect of an anti-cancer drug in a subject diagnosed with cancer, the method including administering to the subject a combination therapy including: an effective amount of 7-ethynyl-5-(2-fluorophenyl)-1-methyl-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one (BZD-1); and an anti-cancer drug.
A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
A rotating detonation combustor includes a nozzle coupled to the combustor body at or near the exhaust opening to choke the exhaust opening. A rotating detonation combustor may include a diverting plate positioned radially inward of the inlet annulus and inlet channels for diverting flow of a mixture in an axial direction. A rotating detonation combustor may include a combustor body including an outer shell at least partially defining a detonation combustion chamber and extending axially from a base toward an exhaust opening of the detonation combustion chamber. The base defines a passageway in fluid communication with the detonation combustion chamber and includes an inlet annulus for axially directing a second fluid into the passageway and a plurality of inlet channels for radially directing a third fluid into at least one of the passageway or the detonation combustion chamber, and the detonation combustion chamber is free of any inner body.
A probe for positron emission tomography (PET) is disclosed. The probe is selected from the group consisting of yersini-abactin (Ybt) labeled with Copper-64; staphylopine (StP) labeled with Copper-64; yersiniabactin (Ybt) labeled with Zirconium-89; and staphylopine (StP) labeled with Zirconium-89.
22+22+2242+2252+2+ product when the one or more single-site dopants has an oxophilicity that is less than the oxophilicity of Cu or greater than the oxophilicity of Ru.
C25B 11/091 - Electrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of at least one catalytic element and at least one catalytic compoundElectrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of two or more catalytic elements or catalytic compounds
A method of determining an initial concentration of an analyte in a sample fluid is provided. The method includes providing a plurality of irreversible probes (182b), the plurality of irreversible probes (182b) each including at least one binding site configured to bind to an analyte (180). The method further includes introducing a sample fluid (140b) to the irreversible probes (182b) allowing binding of the analyte (180) to the irreversible probes (182b) at the binding site, the analyte 180 binding to the at least one of the plurality of irreversible probes (182b) produces a change in a signal having a signal strength. After the signal strength is unchanged for a period of time, the method includes calculating the initial concentration of the analyte in the sample fluid based on the signal strength.
377, and a basic anolyte with an aldehyde therein. The aldehyde reacts with the hydroxyl groups from the catholyte to produce hydrogen and the catholyte reacts water therein with the electrons from the anolyte to also produce hydrogen in a highly Faradaic efficient system. Application of the present disclosure not only provides for production of clean hydrogen, but also offers an approach for aldehyde decontamination.
A method of electrocatalytic dual hydrogenation includes loading a first hydrogenation solution and a second hydrogenation solution into a first hydrogenation compartment and a second hydrogenation compartment of an electrocatalytic hydrogenation assembly, in which the first hydrogenation compartment and the second hydrogenation compartment are separated from an electrochemical cell by a hydrogen-permeable anode and a hydrogen-permeable cathode. The method includes applying and maintaining a voltage to the electrochemical cell to reduce a cathode solution and to oxidize an anode solution to provide hydrogen in the cathodic compartment and/or the anodic compartment. The hydrogen may be absorbed through the hydrogen-permeable anode and/or the hydrogen-permeable cathode and hydrogenate an unsaturated substrate in the first hydrogenation solution and/or the second hydrogenation solution. The method includes producing a first hydrogenated product and a second hydrogenated product with a total Faradic efficiency from 150% to 200%.
C25B 9/23 - Cells comprising dimensionally-stable non-movable electrodesAssemblies of constructional parts thereof with diaphragms comprising ion-exchange membranes in or on which electrode material is embedded
C25B 9/00 - Cells or assemblies of cellsConstructional parts of cellsAssemblies of constructional parts, e.g. electrode-diaphragm assembliesProcess-related cell features
66.
ROTATING DETONATION ENGINES AND RELATED DEVICES AND METHODS
In one embodiment, a combustor (50) includes a nozzle (52) coupled to the combustor body (12) at or near the exhaust opening (26) to choke the exhaust opening (26). In another embodiment, a combustor includes a diverting plate (74) positioned radially inward of the inlet annulus (40) and inlet channels (42) for diverting flow of a mixture in an axial direction. In another embodiment, a combustor (100) includes a combustor body (102) including an outer shell (104) at least partially defining a combustion chamber (108) and extending axially from a hollow base (106) toward an exhaust opening (112) of the combustion chamber (108). The hollow base (106) defines a passageway (126) in fluid communication with the combustion chamber (108) and includes an inlet annulus (142) for axially directing a first fluid (01) into the passageway (126) and a plurality of inlet channels (140) for radially directing a second fluid (F) into at least one of the passageway (126) or the combustion chamber (108), and the combustion chamber (108) is free of any inner body (20).
F23R 7/00 - Intermittent or explosive combustion chambers
F02C 3/14 - Gas-turbine plants characterised by the use of combustion products as the working fluid characterised by the arrangement of the combustion chamber in the plant
F02C 5/00 - Gas-turbine plants characterised by the working fluid being generated by intermittent combustion
67.
Long lasting Opioid Reversal Using Hydrogen Peroxide-Induced Release in Blood
Naloxone variants that are both long lasting and responsive are disclosed. One version of the compound has a boron ester functional group and the antagonist compound is capable of a sustained release of antagonist based on reaction with hydrogen peroxide. In addition, a method of treating opioid overdose is disclosed. The method involves administering a therapeutically effective amount of the formulation described above to a patient in need thereof. Administration occurs either intranasally, sublingually or intranasally and sublingually, wherein if administration occurs intranasally and sublingually administration occurs simultaneously, sequentially or concomitantly.
A method of forming a yellow grease is provided. The method includes delivering a FOG lipid extraction agent into a processing tank. The method further includes preheating an FOG to a temperature of between 35° C. and 95° C. The method further includes mixing the preheated waste grease with the FOG lipid extraction agent in the processing tank to form the yellow grease.
A whole blood anticoagulant composition and system including the composition, wherein the composition includes sodium bicarbonate, mannitol, sodium acetate, and magnesium citrate—and may optionally include sodium bisphosphate and/or adenine. The whole blood storage system may include apparatus that allows for whole blood leukoreduction with pH optimization for improved RBC storage. Such a system can provide leukoreduced whole blood for field medical use, and preserve RBCs and maintain or mostly maintain coagulation activity of the whole blood.
An apparatus may include a processor configured to synthesize a first configuration file associated with a target field-programmable gate array (FPGA), and a second configuration file associated with the target FPGA, wherein first look-up-table (LUT) bits of the first configuration file are the logical inverse of second LUT bits of the second configuration file, and first non-LUT bits of the first configuration file are the same as second non-LUT bits of the second configuration file, and generate a LUT mask indicating which bits of the first configuration file and the second configuration file correspond to the first LUT bits and the second LUT bits by performing a bit-wise exclusive OR operation between the first configuration file and the second configuration file.
G06F 30/331 - Design verification, e.g. functional simulation or model checking using simulation with hardware acceleration, e.g. by using field programmable gate array [FPGA] or emulation
A device for measuring one or more analytes in a sample of interstitial fluid or blood is provided. The device comprises at least one EAB sensor using one or more attached redox couples that measure at least one of the analytes. It also includes at least one means to establish fluid communication between the sensor and the sample. The analytes are selected from the group consisting of progesterone, luteinizing hormone (LH), estrogen, follicle stimulating hormone (FSH), their metabolites, and combinations thereof.
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
A61B 5/1473 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using chemical or electrochemical methods, e.g. by polarographic means invasive, e.g. introduced into the body by a catheter
A device for measuring one or more analytes in a sample fluid is provided. The device includes at least one aptamer sensor comprising a plurality of aptamers. The sensor provides a measurement of at least one of the analytes. In addition, the measurement is affected by changes in temperature (“a temperature-dependent response”). The device also includes a means to establish fluid communication between the at least one aptamer sensor and the sample fluid. Further, the device includes at least one temperature sensor and a means for correcting a measurement error due to the temperature-dependent response.
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
A61B 5/1459 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using optical sensors, e.g. spectral photometrical oximeters invasive, e.g. introduced into the body by a catheter
A61B 5/1473 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using chemical or electrochemical methods, e.g. by polarographic means invasive, e.g. introduced into the body by a catheter
G01N 27/27 - Association of two or more measuring systems or cells, each measuring a different parameter, where the measurement results may be either used independently, the systems or cells being physically associated, or combined to produce a value for a further parameter
Provided herein is a vaccine adjuvant containing an N-terminal domain of osteopontin or a fragment thereof. Also provided are conjugates and fusion proteins containing the N-terminal domain of osteopontin conjugated to a pathogen or a protein derived therefrom. A method for potentiating an immune response to an immunizing antigen is also provided, the method including administering to a subject an effective amount of a vaccine adjuvant containing an N-terminal domain of osteopontin. Also provided is a method of vaccinating a subject against SARS-CoV-2, the method including administering to a subject a fusion protein containing the N-terminal domain of osteopontin and the receptor binding domain of SARS-CoV-2 spike glycoprotein. Cellular vaccines and methods of vaccinating a subject with a cellular vaccine are also provided herein.
A novel composition is provided. The composition is a tetrameric reaction product of heterocyclic 3-thiophenecarboxaldehyde and an aromatic compound, the reaction product being a calix[4]arene. In one embodiment, the present invention is a thiophene functionalized calixarene selected from the group consisting of C-thiopheneresorcin[4]arene and C-thiophenepyrogallol[4]arene. In another embodiment, the thiophene functionalized calixarene further comprises silver nanoparticles.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
C09D 4/00 - Coating compositions, e.g. paints, varnishes or lacquers, based on organic non-macromolecular compounds having at least one polymerisable carbon-to-carbon unsaturated bond
Systems and methods disclosed herein provide training an artificial neural network (ANN) on buffered input and output samples of an original component within a system such that the ANN is configured to produce a degenerate component, the degenerate component configured to generate the same outputs as the original component; comparing the outputs from the original component to outputs of the degenerate component during actual component operation; and in the event of a failure of the original component, replacing the original component with the degenerate component.
An apparatus may comprise a synapse comprising a first reconfigurable field-effect transistor; a second reconfigurable field-effect transistor connected in parallel to the first reconfigurable field-effect transistor; an input voltage applied to each of the first reconfigurable field-effect transistor and the second reconfigurable field-effect transistor corresponding to an input attribute associated with an error computation; and a current sensor measures a saturation drain current of the first reconfigurable field-effect transistor and the second reconfigurable field-effect transistor and determines a Euclidean error based on the saturation drain current of the FETs
G11C 11/22 - Digital stores characterised by the use of particular electric or magnetic storage elementsStorage elements therefor using electric elements using ferroelectric elements
G06N 3/063 - Physical realisation, i.e. hardware implementation of neural networks, neurons or parts of neurons using electronic means
G11C 11/54 - Digital stores characterised by the use of particular electric or magnetic storage elementsStorage elements therefor using elements simulating biological cells, e.g. neuron
H01L 29/78 - Field-effect transistors with field effect produced by an insulated gate
A method for anomaly detection in an operational asset includes collecting a source domain dataset corresponding to a first operating condition of the operational asset, wherein samples from the source domain dataset belong to a healthy class, and a faulty class; collecting a target domain dataset corresponding to a second operation condition of the operational asset, wherein samples from the target domain dataset belong to the healthy class; inputting the source domain dataset and the target domain dataset as input data into a neural network; extracting, by the neural network, features from the input data, wherein a first subset of features is discriminative of the healthy class and a second subset of features is domain invariant; reducing a dimensionality of the features into reduced features; and classifying the reduced features into a normal class and an anomaly class using a one-class classifier.
An implant system for the fusion of the occipitocervical (O-C1) joint is provided. The system has a plate including a horizontal panel, a right vertical panel and a left vertical panel. The horizontal panel has at least two openings. The right vertical panel has at least two openings. The left vertical panel has at least two openings. The system also includes at least four bone fixation fasteners to fix the panels to the occipital condyle and C1 lateral mass using the openings in the panels.
A positive expiratory pressure-generating device for reducing breathlessness in a subject with one or more pulmonary disorders is disclosed. The device is rigid and hollow and can be held in the mouth of the subject. The device has at least one air chamber, at least one opening in the portion of the device that is held in the mouth and at least one additional airflow orifice. The device is configured to increase expiratory resistance and can be supported by the mouth of the subject without the need for additional support by hands, another device or other means.
A63B 23/18 - Exercising apparatus specially adapted for particular parts of the body for improving respiratory function
A63B 21/00 - Exercising apparatus for developing or strengthening the muscles or joints of the body by working against a counterforce, with or without measuring devices
A63B 23/03 - Exercising apparatus specially adapted for particular parts of the body for the head or neck for face muscles
80.
MG ALLOY MESH REINFORCED POLYMER/ECM HYBRID SCAFFOLDS FOR CRITICAL-SIZED BONE DEFECT REGENERATION
The invention relates to biomimetic, biodegradable composites including a magnesium (Mg) alloy mesh and a polymer/extracellular matrix (ECM). These hybrid composites, more particularly, are useful for the fabrication of medical implant devices, e.g., scaffolds, and are effective for bone regeneration. The fabrication process includes creating the Mg alloy mesh, and concurrently electrospinning the polymer and electrospraying the ECM onto the mesh.
A61L 27/36 - Materials for prostheses or for coating prostheses containing ingredients of undetermined constitution or reaction products thereof
A61L 27/44 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
Provided herein are an ionizable lipid compound, a lipid nanoparticle comprising the ionizable lipid compound, a composition comprising an mRNA formulated in the lipid nanoparticle, and a method of delivering an mRNA to a subject or a cell by administering the composition including an mRNA formulated in the lipid nanoparticle to the subject or cell.
C07C 229/22 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms
C07C 229/24 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one carboxyl group bound to the carbon skeleton, e.g. aspartic acid
C07C 229/26 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
Avobenzone complexes are provided, including a complex of avobenzone-RsC5 and a complex of cucurbit[7]uril. Among other uses, the complexes can be used in sunscreen compositions. In one embodiment, the avobenzone complex is from about 0.5 to about 10 weight percent of the sunscreen composition.
An orthopedic implant is provided. The implant includes at least one coating on the surface of the implant. The coating has at least one drug and release of the drug is selectively triggered by inflammation. The coating may comprise one or more ROS-responsive polymers selected from the group consisting of poly(thioketal ß-amino amide) (PTK-BAA), poly(thioacetal ß-amino amide) (PTA-BAA), and poly(ß-amino ester) (PBAE) chemistries.
Systems and methods for controlling a center of gravity (CoG) of a device include one or more weights mechanically coupled to the device and operable to move along one or more body axes of the device, one or more motion sensors configured to determine state information of the device, and one or more processors. The processors are operable to determine that the device is occupied by a user, estimate the CoG of the device based on the state information of the device, determine a CoG deviation based on the CoG of the device and a target CoG, and move the weights to reduce the CoG deviation to less than or equal to a threshold CoG deviation.
G01M 1/12 - Static balancingDetermining position of centre of gravity
A63F 13/20 - Input arrangements for video game devices
G06F 3/01 - Input arrangements or combined input and output arrangements for interaction between user and computer
B64C 17/00 - Aircraft stabilisation not otherwise provided for
B64U 40/20 - On-board mechanical arrangements for adjusting control surfaces or rotorsOn-board mechanical arrangements for in-flight adjustment of the base configuration for in-flight adjustment of the base configuration
85.
EPIGENETIC QUANTIFICATION USING DNA HYBRIDIZATION-BASED SINGLE-MOLECULE IMMUNOFLUORESCENT IMAGING
Disclosed herein is a method of epigenetic quantification using DNA hybridization-based single-molecule immunofluorescent imaging, an ultra-sensitive method of detecting epigenetic modifications in DNA. Via use of probe DNA to capture the DNA fragment of interest and the immunofluorescent imaging to detect modifications, the fluorescent response signal can be detected and quantified at the single-molecule level.
A method for treating a subject having a cutaneous thermal injury is disclosed. The method comprises administering a therapeutically effective amount of a bactericidal compound topically to the injury. Use of a therapeutically effective amount of a bactericidal compound topically for treating a subject having a cutaneous thermal injury is also disclosed. The bactericidal compound comprises a therapeutically effective amount of NaNO2 (A-NO2—) and di-sodium EDTA (Na2-EDTA).
Described herein are methods and devices of detecting a particulate analyte in a sample solution, using an electrochemical cell having an anodic compartment and a cathodic compartment, wherein the anodic and cathodic compartments are separated by a semi-permeable membrane. The sample solution is acidified by applying a positive current to the anodic compartment and maintaining the positive current to permit anions to flow from the cathodic compartment to the anodic compartment through the semi-permeable membrane. The analyte is deposited on an electrode disposed in the anodic compartment by applying a negative current. The deposited analyte is stripped from the electrode and an electrochemical voltammogram is generated by measuring the current as the analyte is stripped from the electrodes. The voltammogram is used to determine the concentration of the analytes in the sample solution based on the generated electrochemical voltammogram.
A method of assessing gut health in a subject is provided. The method involves placing a device on or near the subject's skin and measuring a level of hydrogen gas emanating through the subject's skin. The device includes an electrochemical sensor capable of detecting hydrogen gas and a means of connecting the device to an apparatus having a central processing unit (CPU). The apparatus provides information on hydrogen gas level and the hydrogen gas level is used to assess gut health of the subject.
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
A61B 5/1477 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using chemical or electrochemical methods, e.g. by polarographic means non-invasive
89.
SYNTHETIC AMNIOTIC FLUID COMPOSITIONS COMPRISING URINARY TRYPSIN INHIBITOR AND ASCORBIC ACID, AND METHODS OF USING SAME
Disclosed are synthetic amniotic fluid compositions comprising ulin-A- statin/urinary trypsin inhibitor (UTI) and ascorbic acid and methods of using the disclosed synthetic amniotic fluid compositions, which may be useful for a variety of purposes related to treatment of a fetus, replacement of amniotic fluid, or research uses in which amniotic cells or tissues are used. The synthetic amniotic fluid compositions may be used to minimize and/or reduce risks associated with currently utilized compositions for amnioinfusion, which traditionally include normal saline (NS) and Lactated Ringer's (LR), or to improve amniotic epithelial cell viability and integrity, in vivo and/or in vitro.
A drug delivery device comprising: a first layer comprising a first coaxially electrospun nanofiber membrane; a second layer comprising a second coaxially electrospun nanofiber membrane; a first therapeutic agent integrated into the first coaxially electrospun nanofiber membrane; and a second therapeutic agent integrated into the second coaxially electrospun nanofiber membrane. The second therapeutic agent is different from the first therapeutic agent.
A61K 31/277 - NitrilesIsonitriles having a ring, e.g. verapamil
A61K 31/4188 - 1,3-Diazoles condensed with heterocyclic ring systems, e.g. biotin, sorbinil
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
B23K 26/38 - Removing material by boring or cutting
B32B 5/02 - Layered products characterised by the non-homogeneity or physical structure of a layer characterised by structural features of a layer comprising fibres or filaments
B32B 5/26 - Layered products characterised by the non-homogeneity or physical structure of a layer characterised by the presence of two or more layers which comprise fibres, filaments, granules, or powder, or are foamed or specifically porous one layer being a fibrous or filamentary layer another layer also being fibrous or filamentary
B32B 37/10 - Methods or apparatus for laminating, e.g. by curing or by ultrasonic bonding characterised by the pressing technique, e.g. using direct action of vacuum or fluid pressure
B32B 37/18 - Methods or apparatus for laminating, e.g. by curing or by ultrasonic bonding characterised by the properties of the layers with all layers existing as coherent layers before laminating involving the assembly of discrete sheets or panels only
B32B 38/00 - Ancillary operations in connection with laminating processes
D04H 1/4382 - Stretched reticular film fibresComposite fibresMixed fibresUltrafine fibresFibres for artificial leather
D04H 1/56 - Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties by welding together the fibres, e.g. by partially melting or dissolving in association with fibre formation, e.g. immediately following extrusion of staple fibres
D04H 1/728 - Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres characterised by the method of forming fleeces or layers, e.g. reorientation of fibres the fibres being randomly arranged by electro-spinning
The present disclosure concerns open-end carbon nanotubes assembled as a microelectrode array in electrode sets/micro-electrode sets (ES/micro-ES). The ES/micro-ES includes three electrodes that are made of highly densified multi-walled carbon nanotubes fibers (HD-CNTfs) sectioned into rods embedded in an inert polymer film with exposed open ends of CNTs at the electrode-electrolyte interface. The ES/micro-ES provide miniature electrochemical sensing devices in which all electrodes are based on carbon nanomaterials. The combination of dimensions and orientation provides for highly sensitive electrochemical determination (picomolar) of different electroactive analytes in different electrolyte mediums, where even a single drop of desired analyte solution will be enough for electrochemical characterization.
Provided herein are methods for treating diabetic cardiomyopathy in a patient in need thereof, such as a patient diagnosed with type 1 or type 2 diabetes. The methods generally include administering a therapeutically effective amount of one or more glucose transporter isoform 1 (GLUT1) inhibitors to the patient. Exemplary GLUT1 inhibitors include STF-31, WZB117, phloretin, and BAY-876.
A61K 31/235 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
A61K 31/351 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
A method of inhibiting CXCL1 in one or more natural killer (NK) cells in a subject is provided. The method involves administering one or more pharmaceutically effective doses of metformin to the subject. In another embodiment of the invention, a pharmaceutical composition useful for increasing natural killer cell activity in a subject is provided. The composition includes pembrolizumab, a CXCR2 inhibitor and a pharmaceutically acceptable excipient.
A61K 31/132 - Amines, e.g. amantadine having two or more amino groups, e.g. spermidine, putrescine
A61K 31/341 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A method for detecting multiple pathogens is provided. The method involves linking multiple pathogens to fluorophores and then obtaining emission spectra of the pathogens using a prism- based fluorescence imaging system. In one embodiment, emission spectra of the fluorophores are obtained using optical detection and at least one other aspect of the pathogens is obtained using a silicon chip.
C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
B01L 7/00 - Heating or cooling apparatusHeat insulating devices
C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
The present disclosure concerns RNA aptamers that specifically inhibit the protein-protein interaction between MED1 and an estrogen receptor. As shown herein, the aptamers are specific for the LXXLL recognition motif between MED 1 and an estrogen receptor. The present disclosure further concerns pRNA nanoparticles of the RNA aptamers coupled with a further HER2 aptamer that show HER2 specific uptake and subsequent inhibition of cellular proliferation and metastasis in vitro and in vivo. Furthermore, the pRNA nanoparticles showed no adverse effects, signifying a safe and effective composition to specifically target and control HER2 expressing cells.
Provided herein are implantable biomaterials for promoting regeneration of an injured biological tissue, the biomaterials including piezoelectric materials and an extracellular matrix specific to the injured biological tissue, wherein the piezoelectric materials and the extracellular matrix are electrospun together to provide tissue-specific bioactive piezoelectric nanofiber scaffolds. Also provided herein are methods of fabricating a tissue-specific bioactive piezoelectric nanofiber scaffold and methods of promoting regeneration of injured biological tissue by implanting the disclosed bioactive piezoelectric scaffolds.
E. coliE. coliE. coli Nissle 1917. In one embodiment, the MAM protein has a sequence of [SEQ ID NO: 1], In another embodiment, the bacterium expresses a plasmid having a sequence of [SEQ ID NO: 2].
Methods of treating a patient in need of reperfusion therapy following an ischemic event are provided herein. The method generally involves administering to the patient one or more primary therapeutic agents in combination with onset of reperfusion therapy, wherein the one or more primary therapeutic agents are selected from the group consisting of Krüppel-like factor 5 (KLF5) inhibitors, NADPH oxidase (NOX) inhibitors, and glucose transport (GLUT) inhibitors.
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61K 9/00 - Medicinal preparations characterised by special physical form
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
99.
Microfluidic Chips for Neurological and Other Biological Studies
The present invention involves a compartmentalized microfluidic device using one or more separators. Each separator has a plurality of microfluidic channels and the separators are oriented in a perpendicular direction to the substrate. The vertical integration of the microfluidic components enables realization of 3D device features with high aspect ratio.
Gas diffusion electrode suitable for use in carbon dioxide electrolyzer and methods for making the same. According to one embodiment, the gas diffusion electrode may include a gas diffusion layer and a catalyst layer coupled to the gas diffusion layer. The gas diffusion layer, in turn, may include an electron-conductive domain and a non-conductive hydrophobic domain. The electron-conductive domain includes a plurality of pores. The non-conductive hydrophobic domain randomly occupies a portion of the volume of the pores of the electron-conductive domain and is, itself, sufficiently porous to permit gas transport through the electron-conductive domain, for example, by incompletely filling the pores, thereby leaving spaces in the pores, and/or by being made of an inherently porous material. The electron-conductive domain may be in the form of a metal mesh, a carbon paper, or similar structures. The non-conductive hydrophobic domain may be in the form of sintered polymer particles.
